Overview

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT (observed after GRAZAX treatment).
Phase:
Phase 4
Details
Lead Sponsor:
ALK-Abelló A/S